NL-OMON41136已完成2 期
A 12-week Phase IIa, Double-blind, Placebo-controlled, Randomized Study to Investigate the Efficacy and Safety of AZD7624 in COPD Patients with a History of Frequent Acute Exacerbations while on Maintenance Therapy - D2550C00005 - PoP ExDo
Astra Zeneca0 个研究点目标入组 18 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Provision of signed and dated written informed consent prior to any study specific procedures
- •2.. Male and females aged 40 - 85 years
- •3. Females must have a negative pregnancy test at Visit 1, must not be lactating and must be of non-childbearing potential, by fulfilling one of the following criteria:
- •-Postmenopausal defined as amenorrhoea for at least 12 months or more following cessation of all possible exogenous hormonal treatments and luteinising hormone (LH) and follicle-stimulating hormone (FSH) levels in the postmenopausal range (at Visit 1)
- •-Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation;6. Clinical diagnosis of COPD for more than 1 year at Visit 1, according to the GOLD 2014 guidelines
- •7. Stable COPD maintenance treatment with at least ICS/LABA for at least 2 months prior to enrolment (Visit 1), to be continued unchanged during the study
- •8. A post-bronchodilator FEV1/FVC <0.70 and a post-bronchodilator FEV1 <=70% of the predicted normal value (at Visit 2)
- •9. Documented history of 2 or more moderate to severe COPD exacerbations (requiring treatment with systemic corticosteroid and/or with antibiotics and/or emergency room visit and/or hospitalisation) within 12 months of randomisation (Visit 3), but not within the last 6 weeks before randomisation (Visit 3). At least one of the exacerbations should be while on current COPD maintenance therapy (at least ICS/LABA)
排除标准
- •1. Involvement in the planning and conduct of the study (applies to both AstraZeneca staff and staff at third party vendor or at the investigational sites);2. Previous randomisation to treatment in the present study (at Visit 1);3. Participation in another clinical study with any novel investigational medicinal product within 3 months before the first dose of investigational product in this study (at Visit 3) ;4. Previously intake of any p38 inhibitor (same class as AZD7624);5. Participation in, or scheduled for an intensive COPD rehabilitation programme at any time during the study (N.B. patients are allowed to be in the maintenance phase of a rehabilitation programme);6. Planned in-patient surgery or hospitalisation during the study;7. Significant disease or disorder other than COPD (e.g. cardiovascular; pulmonary as e.g. tuberculosis and cystic fibrosis; gastrointestinal, liver; neurological; musculoskeletal; endocrine; metabolic; malignant; psychiatric; major physical impairment) which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or influence the results of the study, or the patient*s ability to participate in the study (at Visit 1) ;8. Asthma as a primary or main diagnosis according to the Global Initiative for Asthma (GINA) guidelines (GINA 2013) or other accepted guidelines. Patients with a past medical history of asthma (e.g. childhood or adolescence) may be included;9. Any clinically relevant abnormal findings in clinical chemistry, haematology and urinalysis, which, in the opinion of the investigator, may put the patient at risk because of participation in the study (at Visit 2 and 3);11. Any clinically relevant abnormal findings in physical examination, pulse or blood pressure which, in the opinion of the investigator, may put the patient at risk because of participation in the study (at Visit 1, 2 and 3);12. Any positive result on screening for serum hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV);13.History or family history of muscle diseases (at Visit 1);14.Abnormal vital signs, after 10 minutes supine rest, defined as any of the following (at Visit 1, 2 and 3):;*-Systolic blood pressure (SBP) above 150 mmHg;*-Diastolic blood pressure (DBP) above 90 mmHg;*-Pulse <40 or >100 bpm;15.Prolonged QTcF >450 ms or family history of long QT syndrome or sudden death at young age. PR(PQ) interval prolongation of clinical significance, PR(PQ) > 250 ms. Intermittent second or third degree atrioventricular (AV) block, or AV dissociation. QRS duration >=120ms. Patients who are not in sinus rhythm. Patients with persistent, and /or recurrent symptomatic tachyarrhythmias, as well as patients with an implantable cardioverter-defibrillator (ICD) or a permanent pacemaker. Patients on anticoagulation treatment.;16.Unstable angina pectoris or stable angina pectoris classified higher than Canadian Cardiovascular Society (CSS) class 2. History of hospitalisation within 12 months caused by heart failure or a diagnosis of heart failure higher than New York Heart Association (NYHA) class II. Acute myocardial infarction within 6 months of screening (Visit 1).;17. History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD7624;18. Any exacerbation (defined as use o
研究者
相似试验
进行中（未招募）
1 期
A 12-week study to investigate the effect and safety of AZD7624 treatment compared to placebo (inactive substance) in COPD Patients when administered together with the patients' regular COPD TherapyChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 17.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2014-001053-16-NLAstraZeneca AB212
进行中（未招募）
不适用
A 12-week, Phase-II, Double-Blind, Placebo-Controlled, Randomised,Parallel-Group, Multi-Centre Study to Assess the Effect of 60 mg AZD9668Administered Orally Twice Daily on Structural Changes in the Airwaysby Multi-Slice Computed Tomography (MSCT) in Patients with ChronicObstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.0Level: LLTClassification code 10010952Term: COPDEUCTR2009-014594-40-NLAstraZeneca AB50
进行中（未招募）
不适用
A 12-week, Phase-II, Double-Blind, Placebo-Controlled, Randomised,Parallel-Group, Multi-Centre Study to Assess the Effect of 60 mg AZD9668Administered Orally Twice Daily on Structural Changes in the Airwaysby Multi-Slice Computed Tomography (MSCT) in Patients with ChronicObstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.0Level: LLTClassification code 10010952Term: COPDEUCTR2009-014594-40-DKAstraZeneca AB50
进行中（未招募）
1 期
A Study of JZP385 in Adults with Moderate to Severe Essential Tremor (ET)EUCTR2020-002463-61-ESCavion, Inc., a subsidiary of Jazz Pharmaceuticals, Inc.400
进行中（未招募）
1 期
A Study of JZP385 in Adults with Moderate to Severe Essential Tremor (ET)Essential Tremor (ET)MedDRA version: 21.1Level: PTClassification code 10015496Term: Essential tremorSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-002463-61-DECavion, Inc., a subsidiary of Jazz Pharmaceuticals, Inc.400